Comment from The PPD clinical research business of Thermo Fisher Scientific
AnonymousOtherBusiness
PPD, the clinical research business of Thermo Fisher Scientific, submits the attached formal response to the U.S. Food and Drug Administration’s Request for Information on the AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program (Docket No. FDA-2026-N-4390). Our submission addresses Sections A. Challenges and B. Potential of AI.